GlobalData has released its new
Country report, PharmaPoint: Rheumatoid Arthritis India Drug Forecast and
Market Analysis Event-Driven Update. The RA market is currently very dynamic,
with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and
novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab
and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib.
These compounds will challenge the current biologics in the attempt to dislodge
the stronghold of the TNF inhibitors, if their safety and efficacy profiles are
proven once they enter the market.
To check out the Complete table of
contents, visit: http://www.marketresearchreports.biz/analysis-details/pharmapoint-rheumatoid-arthritis-india-drug-forecast-and-market-analysis-event-driven-update
Indian physicians included in our
study typically follow guidelines such as ACR or EULAR, but also follow their
own clinical experience. In India, the process to diagnosis a patient with RA
usually begins with the PCP or GP regardless of which potential stage the
patient is in, then progresses with the referral to a rheumatologist for
further diagnosis and treatment as this occurs about 32% of the time. Also,
most people seeking treatment are within the 35-55-year-old group. Within this
age group, females and males are equally distributed according to our physician
experts.
Scope
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2011 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India rheumatoid arthritis market.
To Buy The Copy of This Report
Visit: http://www.marketresearchreports.biz/analysis/158931
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in India
- Obtain sales forecast from 2011-2022 in India
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
Really Amazing Post. Thanks for sharing useful information. Lucintel’s Medical Market Reports provide quantitative and qualitative data analysis for the global and regional markets
ReplyDelete